Dianthus Therapeutics, Inc.
DNTH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $6 | $3 | $6 | $1 |
| % Growth | 120.6% | -56% | 334.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $6 | $3 | $6 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $83 | $33 | $29 | $13 |
| G&A Expenses | $25 | $18 | $7 | $2 |
| SG&A Expenses | $25 | $18 | $7 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $108 | $51 | $36 | $15 |
| Operating Income | -$102 | -$48 | -$30 | -$13 |
| % Margin | -1,633.7% | -1,704.7% | -462.9% | -886.6% |
| Other Income/Exp. Net | $17 | $5 | $1 | -$0 |
| Pre-Tax Income | -$85 | -$44 | -$28 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$85 | -$44 | -$28 | -$13 |
| % Margin | -1,362.8% | -1,541.2% | -443.8% | -888.1% |
| EPS | -2.55 | -8.45 | -7.6 | -3.82 |
| % Growth | 69.8% | -11.2% | -99% | – |
| EPS Diluted | -2.55 | -8.45 | -7.6 | -3.82 |
| Weighted Avg Shares Out | 33 | 5 | 4 | 3 |
| Weighted Avg Shares Out Dil | 33 | 5 | 4 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $17 | $5 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$101 | -$48 | -$30 | -$13 |
| % Margin | -1,627.1% | -1,692.1% | -460.6% | -886.6% |